Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen® From Eisai (U.S.)

On March 31, 2014 Otsuka Pharmaceutical reported an agreement with Eisai to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727 (Press release Otsuka, MAR 31, 2014, View Source [SID:1234500356]).
Rights Acquired From Eisai:
Exclusive rights to the development and sale of DNA methylation inhibitor Dacogen, an intravenous formulation of decitabine (generic name), in the U.S., Canada, and Japan in addition to the licensing rights worldwide excluding Mexico. Eisai will retain the rights in Mexico. Janssen Pharmaceutical Companies will retain its worldwide development and commercialization rights (excluding the U.S., Canada, Mexico and Japan).
Patent rights to metabolic enzyme inhibitor E7727, currently in pre-clinical development by Otsuka’s U.S. subsidiary Astex Pharmaceuticals, Inc. E7727 is in development together with decitabine to form the combination product ASTX727 (an oral hypomethylating agent), which if approved would become the first oral formulation of decitabine.

Otsuka will continue its existing decitabine-related business through Astex Pharmaceuticals, a U.S. subsidiary, concurrent with advancing clinical development of ASTX727 with the aim to provide an alternative, early-stage option in the treatment of MDS.

Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU

On March 31, 2014 GlaxoSmithKline reported that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorisation for Votrient (pazopanib) (Press release GlaxoSmithKline, MAR 31, 2014, View Source;votrient—pazopanib–as-maintenance-therapy-.html [SID:1234500354]). This application, made in August 2013, was related to the additional indication for the maintenance treatment of women with FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal cancer who had not progressed after receiving first-line chemotherapy.
GSK has taken the decision because the data from the planned second interim Overall Survival (OS) analysis of the phase III study (NCT01227928) did not support the overall benefit:risk for Votrient in this indication. The hazard ratio for OS was 1.076 (p=0.4985; 95% CI: 0.868; 1.333).These data will be submitted for presentation at an upcoming medical congress. GSK does not intend to progress further with this indication in other countries.
The regulatory submission for Votrient in this indication was based on the results from AGO-OVAR-16 (VEG110655), a randomised, double-blind, phase III, placebo-controlled study which evaluated the efficacy and safety of pazopanib monotherapy as compared with placebo in women with FIGO stage II-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease had not progressed after first-line chemotherapy.

Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427

On March 31, 2014 Curis reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND (Press release Curis, MAR 31, 2014, View Source [SID:1234500345]). The FDA also indicated that detailed official correspondence regarding the determination will be released in the near future. Curis will provide additional details, if applicable, based upon further communications from the FDA as they become available.
In November 2013, CUDC-427’s Phase 1 study (NCT01908413) in patients with solid tumors or lymphoma was placed on partial clinical hold following the death of a patient who progressed to liver failure approximately one month following the discontinuation of CUDC-427 dosing. Under the partial clinical hold, no new patients were to be enrolled in the study until Curis provided the FDA with the requested data and analyses of all patients treated with CUDC-427, together with a protocol amendment found to be acceptable to the FDA.

DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer

On May 27, 2014 DepYmed Inc., a joint venture of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) and Cold Spring Harbor Laboratory, reported the validation of Trodusquemine (MSI-1436) as a therapeutic candidate for HER2-positive breast cancer (Press release, Ohr Pharmaceutical, MAR 27, 2014, View Source [SID:1234512310]). Trodusquemine is the Company’s inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B). The results were published online on May 20, 2014 in Nature Chemical Biology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. In approximately 1 out of every 4 breast cancers, tumor cells make an excess of HER2 due to a gene amplification. HER2-positive breast cancers tend to be aggressive and the prognosis for patients is poor. The drug Herceptin (trastuzumab) is a first-line treatment for many women with HER2-positive breast cancer, but in most cases resistance develops within a year. It is anticipated that alternative therapies which act either alone or in combination with Herceptin may enhance patient outcomes.

In a paper entitled "Targeting the Disordered C Terminus of PTP1B With an Allosteric Inhibitor" a multi-institution team led by Professor Nicholas Tonks of Cold Spring Harbor Laboratory reports that it has found a means of inhibiting PTP1B, expression of which is upregulated in HER2-positive breast cancer. They provide compelling evidence of PTB1B as a therapeutic target in HER2-positive breast cancer.

PTB1B is a well-characterized target for several major diseases, including diabetes and obesity. However, it has been a challenging target for therapeutic development due to the chemical properties of the enzyme at its active site. "Novel approaches are required to exploit this important target fully," Dr. Tonks observes. In the approach reported in the newly published paper, Trodusquemine has been identified as a selective, allosteric inhibitor of PTP1B that exerts its effects outside the active site of the enzyme.

Dr. Tonks and his team tested Trodusquemine in several mouse models of HER2-dependent breast cancer. They showed that in animals treated with Trodusquemine, there was extensive inhibition of tumor burden and prevention of metastasis to the lung. They also demonstrated that it was inhibition of PTP1B that antagonized signaling by HER2 proteins in the treated animals.

"We are pleased with the publication of this important paper on Trodusquemine in breast cancer," said Dr. Irach Taraporewala, President and Chief Executive Officer of Ohr Pharmaceutical. "These results build on data from earlier studies showing PTP1B to be a tumor promoter and suggest it may be a viable therapeutic target in HER2-positive breast cancer. This form of breast cancer is very aggressive and difficult to treat. Many women ultimately build up a resistance to current treatments, so it is important to identify additional therapeutic agents for intervention."

In other studies, Trodusquemine has been shown to cross the blood-brain barrier, which enhances its potential applications. It has been well tolerated in dose-escalation clinical studies completed to date in over 65 patients. Novel analogs of Trodusquemine have also been identified that are potent inhibitors of PTP1B and have potential delivery route advantages.

A Phase I clinical trial evaluating Trodusquemine in HER2-positive breast cancer patients is planned for later this year and will be conducted at North Shore-Long Island Jewish Hospital.

(Press release, Prolynx, MAR 27, 2014, View Source [SID:1234504740])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!